Literature DB >> 34155063

Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium.

Colette P Davis1, Elisa V Bandera2, Traci N Bethea3, Fabian Camacho4, Charlotte E Joslin5, Anna H Wu6, Alicia Beeghly-Fadiel7, Patricia G Moorman8, Evan R Myers9, Heather M Ochs-Balcom10, Lauren C Peres11, Will T Rosenow4, Veronica W Setiawan6, Lynn Rosenberg12, Joellen M Schildkraut13, Holly R Harris14,15.   

Abstract

BACKGROUND: Genital powder use is more common among African-American women; however, studies of genital powder use and ovarian cancer risk have been conducted predominantly in White populations, and histotype-specific analyses among African-American populations are limited.
METHODS: We used data from five studies in the Ovarian Cancer in Women of African Ancestry consortium. Participants included 620 African-American cases, 1,146 African-American controls, 2,800 White cases, and 6,735 White controls who answered questions on genital powder use prior to 2014. The association between genital powder use and ovarian cancer risk by race was estimated using logistic regression.
RESULTS: The prevalence of ever genital powder use for cases was 35.8% among African-American women and 29.5% among White women. Ever use of genital powder was associated with higher odds of ovarian cancer among African-American women [OR = 1.22; 95% confidence interval (CI) = 0.97-1.53] and White women (OR = 1.36; 95% CI = 1.19-1.57). In African-American women, the positive association with risk was more pronounced among high-grade serous tumors (OR = 1.31; 95% CI = 1.01-1.71) than with all other histotypes (OR = 1.05; 95% CI = 0.75-1.47). In White women, a significant association was observed irrespective of histotype (OR = 1.33; 95% CI = 1.12-1.56 and OR = 1.38; 95% CI = 1.15-1.66, respectively).
CONCLUSIONS: While genital powder use was more prevalent among African-American women, the associations between genital powder use and ovarian cancer risk were similar across race and did not materially vary by histotype. IMPACT: This is one of the largest studies to date to compare the associations between genital powder use and ovarian cancer risk, overall and by histotype, between African-American and White women. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34155063      PMCID: PMC8419086          DOI: 10.1158/1055-9965.EPI-21-0162

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Genital use of talc and risk of ovarian cancer: a meta-analysis.

Authors:  Wera Berge; Kenneth Mundt; Hung Luu; Paolo Boffetta
Journal:  Eur J Cancer Prev       Date:  2018-05       Impact factor: 2.497

2.  Talc use and ovarian cancer: epidemiology between a rock and a hard place.

Authors:  Nicolas Wentzensen; Sholom Wacholder
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

3.  Perineal talc exposure and risk of ovarian carcinoma.

Authors:  S Chang; H A Risch
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

4.  Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.

Authors:  Katie M O'Brien; Shelley S Tworoger; Holly R Harris; Garnet L Anderson; Clarice R Weinberg; Britton Trabert; Andrew M Kaunitz; Aimee A D'Aloisio; Dale P Sandler; Nicolas Wentzensen
Journal:  JAMA       Date:  2020-01-07       Impact factor: 56.272

5.  Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES).

Authors:  Joellen M Schildkraut; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul Terry; Sydnee Crankshaw; Fabian Camacho; Frances Wang; Patricia G Moorman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-12       Impact factor: 4.254

6.  Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Authors:  Kathryn L Terry; Stalo Karageorgi; Yurii B Shvetsov; Melissa A Merritt; Galina Lurie; Pamela J Thompson; Michael E Carney; Rachel Palmieri Weber; Lucy Akushevich; Wei-Hsuan Lo-Ciganic; Kara Cushing-Haugen; Weiva Sieh; Kirsten Moysich; Jennifer A Doherty; Christina M Nagle; Andrew Berchuck; Celeste L Pearce; Malcolm Pike; Roberta B Ness; Penelope M Webb; Mary Anne Rossing; Joellen Schildkraut; Harvey Risch; Marc T Goodman
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-12

7.  Statistical methodologies to pool across multiple intervention studies.

Authors:  Shrikant I Bangdiwala; Alok Bhargava; Daniel P O'Connor; Thomas N Robinson; Susan Michie; David M Murray; June Stevens; Steven H Belle; Thomas N Templin; Charlotte A Pratt
Journal:  Transl Behav Med       Date:  2016-06       Impact factor: 3.046

8.  Racial Differences in Population Attributable Risk for Epithelial Ovarian Cancer in the OCWAA Consortium.

Authors:  Lauren C Peres; Traci N Bethea; Tareq F Camacho; Elisa V Bandera; Alicia Beeghly-Fadiel; Deanna L Chyn; Holly R Harris; Charlotte E Joslin; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Will Rosenow; V Wendy Setiawan; Anna H Wu; Lynn Rosenberg; Joellen M Schildkraut
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

9.  Motivations for Intravaginal Product Use among a Cohort of Women in Los Angeles.

Authors:  Joelle M Brown; Eugenie Poirot; Kristen L Hess; Stephen Brown; Michele Vertucci; Marjan Hezareh
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

10.  Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.

Authors:  Lauren C Peres; Harvey Risch; Kathryn L Terry; Penelope M Webb; Marc T Goodman; Anna H Wu; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Ani Manichaikul; Sarah E Abbott; Fabian Camacho; Susan J Jordan; Christina M Nagle; Mary Anne Rossing; Jennifer A Doherty; Francesmary Modugno; Kirsten Moysich; Roberta Ness; Andrew Berchuck; Linda Cook; Nhu Le; Angela Brooks-Wilson; Weiva Sieh; Alice Whittemore; Valerie McGuire; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Chiuchen Tseng; Malcom Pike; Joellen M Schildkraut
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.